AEGiS-FDA: FDA licensing of donor screening test for antibodies to HIV type 1, groups M and O, and HIV type 2 Food and Drug AdministrationImportant note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow


FDA licensing of donor screening test for antibodies to HIV type 1, groups M and O, and HIV type 2

Food and Drug Administration - September 29, 2009
Richard Klein & Kimberly Struble

The Food and Drug Administration (FDA) licensed, on September 18, 2009, the Abbott Prism HIV O Plus assay, a new screening tool designed to detect the presence of antibodies to the two types of the virus that causes AIDS, HIV 1 and HIV 2. Both types can be transmitted by sexual contact, through blood, and by mother to child transmission.

The new assay is one of five assays that run on the fully automated Abbott Prism System.

HIV type 1 consists of various subgroups, including group M, the most common subgroup of the virus in the United States, and group O, found primarily in Cameroon and other areas of West Africa.

HIV type 2 is found mostly in West Africa. Both types have been detected in the United States and Europe.

The Abbott Prism HIV O Plus assay detects antibodies to HIV type 1, groups M and O, and HIV type 2. It is the second donor screening test licensed for the detection of antibodies to HIV type 1, group O.

The Abbott Prism HIV O Plus assay is licensed to screen donated blood and blood specimens from other living donors (e.g., organ or tissue donors) for these specific types of HIV and subgroups of HIV type 1. The assay is also licensed to screen specimens from organ donors when specimens are obtained while the donorÆs heart is still beating and from cadavers. Positive results from the screening test require confirmation from supplemental tests.

The Abbott Prism HIV O Plus assay and the Abbot Prism system are manufactured by Abbott Laboratories, Abbott Park, Ill.

Richard Klein

Office of Special Health Issues

Food and Drug Administration

Kimberly Struble

Division of Antiviral Drug Products

Food and Drug Administration
090929
FD090902

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .